These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 28008511)

  • 1. Biochemical and biophysical conditions for blood clot lysis.
    Šabovič M; Blinc A
    Pflugers Arch; 2000 Jan; 440(Suppl 1):R134-R136. PubMed ID: 28008511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and biophysical conditions for blood clot lysis.
    Sabovic M; Blinc A
    Pflugers Arch; 2000; 440(5 Suppl):R134-6. PubMed ID: 11005642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
    Sabovic M; Lijnen HR; Keber D; Collen D
    Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Turbulent axially directed flow of plasma containing rt-PA promotes thrombolysis of non-occlusive whole blood clots in vitro.
    Tratar G; Blinc A; Strukelj M; Mikac U; Sersa I
    Thromb Haemost; 2004 Mar; 91(3):487-96. PubMed ID: 14983224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate.
    Weisel JW; Litvinov RI
    Cardiovasc Hematol Agents Med Chem; 2008 Jul; 6(3):161-80. PubMed ID: 18673231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of staphylokinase, streptokinase and tissue-type plasminogen activator on the lysis of retracted human plasma clots and fibrinolytic plasma parameters in vitro.
    Hauptmann J; Glusa E
    Blood Coagul Fibrinolysis; 1995 Sep; 6(6):579-83. PubMed ID: 7578902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
    Trusen B; Ries M; Zenker M; Rauh M; Beinder E; Keuper H; Harms D
    Semin Thromb Hemost; 1998; 24(6):599-604. PubMed ID: 10066156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MASP-1 of the complement system alters fibrinolytic behaviour of blood clots.
    Jenny L; Noser D; Larsen JB; Dobó J; Gál P; Pál G; Schroeder V
    Mol Immunol; 2019 Oct; 114():1-9. PubMed ID: 31325724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R; Black J; Gurewich V
    J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of flow on lysis of plasma clots in a plasma environment.
    Sakharov DV; Rijken DC
    Thromb Haemost; 2000 Mar; 83(3):469-74. PubMed ID: 10744155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy.
    Sakharov DV; Nagelkerke JF; Rijken DC
    J Biol Chem; 1996 Jan; 271(4):2133-8. PubMed ID: 8567670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clot penetration and retention by plasminogen activators promote fibrinolysis.
    Marcos-Contreras OA; Ganguly K; Yamamoto A; Shlansky-Goldberg R; Cines DB; Muzykantov VR; Murciano JC
    Biochem Pharmacol; 2013 Jan; 85(2):216-22. PubMed ID: 23098998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An experimental and theoretical study on the dissolution of mural fibrin clots by tissue-type plasminogen activator.
    Wootton DM; Popel AS; Alevriadou BR
    Biotechnol Bioeng; 2002 Feb; 77(4):405-19. PubMed ID: 11787013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced plasminogen binding and delayed activation render γ'-fibrin more resistant to lysis than γA-fibrin.
    Kim PY; Vu TT; Leslie BA; Stafford AR; Fredenburgh JC; Weitz JI
    J Biol Chem; 2014 Oct; 289(40):27494-503. PubMed ID: 25128532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysing patterns of retracted blood clots with diffusion or bulk flow transport of plasma with urokinase into clots--a magnetic resonance imaging study in vitro.
    Blinc A; Keber D; Lahajnar G; Stegnar M; Zidansek A; Demsar F
    Thromb Haemost; 1992 Dec; 68(6):667-71. PubMed ID: 1287880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clot penetration and fibrin binding of amediplase,a chimeric plasminogen activator (K2 tu-PA).
    Rijken DC; Barrett-Bergshoeff MM; Jie AF; Criscuoli M; Sakharov DV
    Thromb Haemost; 2004 Jan; 91(1):52-60. PubMed ID: 14691568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic resonance imaging of retracted and nonretracted blood clots during fibrinolysis in vitro.
    Blinc A; Keber D; Lahajnar G; Zupancic I; Zorec-Karlovsek M; Demsar F
    Haemostasis; 1992; 22(4):195-201. PubMed ID: 1468722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling fibrinolysis: a 3D stochastic multiscale model.
    Bannish BE; Keener JP; Fogelson AL
    Math Med Biol; 2014 Mar; 31(1):17-44. PubMed ID: 23220403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disintegration and reorganization of fibrin networks during tissue-type plasminogen activator-induced clot lysis.
    Meh DA; Mosesson MW; DiOrio JP; Siebenlist KR; Hernandez I; Amrani DL; Stojanovich L
    Blood Coagul Fibrinolysis; 2001 Dec; 12(8):627-37. PubMed ID: 11734662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.